Elevated serum level of glycolipid sulfotransferase in patients with hepatocellular carcinoma.
Activity of glycolipid sulfotransferase (cerebroside sulfotransferase) in serum was elevated in 21 (33%) of 63 patients with hepatocellular carcinoma (HCC, mean +/- S.E., 349 +/- 32 pmol/ml per h, n = 63, P less than 0.001) compared to healthy subjects (172 +/- 12, n = 85). Ho significant elevation of the sulfotransferase level was observed in liver cirrhosis (219 +/- 28, n = 10) in which many of biochemical HCC markers increase concomitantly. The elevation of sulfotransferase was independent of the production of alpha-fetoprotein and of aminotransferase levels in HCC, providing complementary value for alpha-fetoprotein-negative HCC cases. However, the sulfotransferase levels (234 +/- 21, n = 32, P less than 0.01) in sera from patients with renal cell carcinoma, in whose involved tissues the enzyme was demonstrated to increase markedly, were less than in HCC.
Gasa
S
S
Biochemistry Laboratory, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan.
Casl
M T
MT
Jin
T
T
Kamio
K
K
Uehara
Y
Y
Miyazaki
T
T
Makita
A
A
D006528:Carcinoma, Hepatocellular / Q000201:enzymology*; D006509:Hepatitis B / Q000201:enzymology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008107:Liver Diseases / Q000201:enzymology; D008113:Liver Neoplasms / Q000201:enzymology*; D015238:Sulfotransferases; D013466:Sulfurtransferases / Q000097:blood*; D000509:alpha-Fetoproteins / Q000378:metabolism
D000509:alpha-Fetoproteins; D013466:Sulfurtransferases; D015238:Sulfotransferases; C020556:galactosylceramide sulfotransferase